Status In progress
Developed As CG

Provisional Schedule

Scoping workshop: TBC
Consultation on draft scope with stakeholders: TBC
Consultation on draft guideline with stakeholders: TBC
Publication date: TBC

Project Team

Project lead Clifford Middleton
Project management coordination Trudie Willingham

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 September 2016 NICE has decided that the development of a hepatitis C clinical guideline should continue to be paused until there is stability in the availability of treatments and the cost to the NHS of the drugs. Registered stakeholders will be alerted if the guideline restarts its development. If you have any queries, please contact nice@nice.org.uk
28 January 2016 NICE has taken the decision to continue to pause the development of the clinical guideline for Hepatitis C. NICE’s technology appraisals continue to evaluate new pharmacological therapies and the role of the guideline will be re-considered when these have been produced. If you have any queries on this, please contact Hema Ali (hema.ali@nice.org.uk)
30 October 2015 - 13 November 2015 Committee chair recruitment
27 October 2015 As you may be aware, following stakeholder feedback, NICE took the decision in January 2014 to pause the development of the clinical guideline for Hepatitis C until NICE technology appraisals evaluating new pharmacological therapies had published. NICE is now in a position to re-commence work on this guideline in the scoping phase. We will therefore be holding a second stakeholder workshop and re-consulting on the draft scope. The workshop will take place on 2 February 2016, with the draft scope consultation running from 25 February 2016 - 24 March 2016.
26 October 2015 Stakeholder list updated
22 January 2014

In consultation with stakeholders, NICE has taken the decision to pause the development of the clinical guideline for Hepatitis C until NICE technology appraisals evaluating new pharmacological therapies have published. More details on the development of these therapies, specifically sofosbuvir for treating chronic hepatitis C, is available on the Hepatitis C (chronic) - sofosbuvir page.

NICE will re-consult on the proposed scope for the hepatitis C guideline and will alert all registered stakeholders when this occurs. The stakeholder comments table and equalities impact assessment form for the guideline have been published on the website in line with standard procedure.

14 November 2013 Consultation on the draft scope is complete and the scope is being modified in the light of comments received. When completed it will be posted on the website. It will define what aspects of care the guideline will cover and to whom it will apply.The National Collaborating Centre and the Institute are in the process of agreeing details of the workplan including how the development will progress, the membership of the Guideline Development Group and timescales.
2 October 2013 The draft scope is out for consultation with stakeholders. The scope defines what aspects of care the guideline will cover and to whom it will apply. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed, by the deadline shown.
15 February 2013 The remit was received from the Department of Health and the Welsh Assembly Government in November 2012.

For further information on the guideline development process, please read how we develop NICE guidelines